LATITUDE - Zytiga & ADT

In addition to the STAMPEDE presentation at ASCO:

"Study findings indicated abiraterone acetate plus prednisone, in combination with ADT, reduced the risk of death by 38 percent compared to placebo plus ADT ... Median OS for the abiraterone acetate plus prednisone in combination with ADT arm was not reached, while the median OS for the placebo plus ADT arm was 34.7 months. Additional study results found abiraterone acetate plus prednisone, in combination with ADT, decreased the risk of progression or death rPFS by 53 percent compared to placebo plus ADT in patients with mHNPC ... Median rPFS was 33.0 months in the abiraterone acetate plus prednisone with ADT group, compared to 14.8 months with placebo plus ADT."

Unlike STAMPEDE, participants were all metastatic cases:

-Patrick

1 Reply

oldestnewest
  • I'd be annoyed if I was among the placebo group and found myself on my deathbed. I guess it has to be done this way. Is that what they mean when they say "take one for the team?"

You may also like...